FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Secur...
January 13 2020 - 3:44PM
Business Wire
Bernstein Liebhard, a nationally acclaimed investor rights law
firm, reminds investors of the deadline to file a lead plaintiff
motion in a securities class action lawsuit filed on behalf of
investors who purchased or acquired shares of Lipocine Inc.
("Lipocine" or the "Company") (NASDAQ: LPCN) from March 27, 2019 to
November 8, 2019, inclusive (the "Class Period"). The lawsuit filed
in the United States District Court for the District of Utah
alleges violations of the Securities Exchange Act of 1934.
If you purchased Lipocine securities, and/or would like to
discuss your legal rights and options please visit LPCN
Shareholder Class Action Lawsuit or contact Matthew E. Guarnero
toll free at (877) 779-1414 or MGuarnero@bernlieb.com.
The Complaint alleges that throughout the Class Period,
Defendants made materially false and misleading statements
regarding the Company’s business, operational and compliance
policies. Specifically, Defendants made false and/or misleading
statements and/or failed to disclose that: (i) the results from
Lipocine’s clinical studies of TLANDO were insufficient to
demonstrate the drugs efficacy; (ii) accordingly, Lipocine’s third
NDA for TLANDO was highly likely to be found deficient by the FDA;
and (iii) as a result, the Company’s public statements were
materially false and misleading at all relevant times.
On November 11, 2019, Lipocine issued a press release announcing
receipt of a CRL from the FDA regarding its NDA for TLANDO. In the
press release, Lipocine advised investors that the FDA had again
rejected the NDA for TLANDO this time because an efficacy trial had
not met three of its secondary endpoints. On this news, Lipocine’s
stock price fell $1.93 per share, or 70.7%, to close at $0.80 per
share on November 11, 2019.
If you purchased Lipocine securities, and/or would like to
discuss your legal rights and options please visit
https://www.bernlieb.com/cases/lipocineinc-lpcn-shareholder-class-action-lawsuit-stock-fraud-218/apply/
or contact Matthew E. Guarnero toll free at (877) 779-1414
or MGuarnero@bernlieb.com.
If you wish to serve as lead plaintiff, you must move the Court
no later than January 14, 2020. A lead plaintiff is a
representative party acting on behalf of other class members in
directing the litigation. Your ability to share in any recovery
doesn’t require that you serve as lead plaintiff. If you choose to
take no action, you may remain an absent class member.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5
billion for its clients. In addition to representing individual
investors, the Firm has been retained by some of the largest public
and private pension funds in the country to monitor their assets
and pursue litigation on their behalf. As a result of its success
litigating hundreds of lawsuits and class actions, the Firm has
been named to The National Law Journal’s “Plaintiffs’ Hot List”
thirteen times and listed in The Legal 500 for ten consecutive
years.
ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New York 10016, (212) 779-1414. The
lawyer responsible for this advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not guarantee or
predict a similar outcome with respect to any future matter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200113005892/en/
Matthew E. Guarnero Bernstein Liebhard LLP
http://www.bernlieb.com (877) 779-1414 MGuarnero@bernlieb.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Sep 2023 to Sep 2024